Subscribe to Daily Review - your favourite M&A deals update.

Submit Deal

ASTELLAS PHARMA INC

HQ - Tokyo

Summary

Astellas Pharma is a pharmaceutical company conducting business in more than 70 countries around the world.

Deals Overview

Total Deals11

Valued Deals9

Total Value£ 11.78 B

Avg. Deal Size£ 1.31 B

Market Context

Senior Management

Masafumi Nogimori
President and CEO
Naoki Okamura
President and CEO
Atsushi Kitamura
CFO

Sort

propella therapeutics

HQ - United States

Pharmaceuticals

22 Dec 2023

Investment Date

100%

Stake

£ 137 M

Deal Value

iveric bio

HQ - United States

Biotechnology

11 Jul 2023

Investment Date

100%

Stake

£ 4.69 B

Deal Value

iota biosciences

HQ - United States

Biotechnology

29 Oct 2020

Investment Date

100%

Stake

£ 97 M

Deal Value

osi pharmaceuticals

HQ - United States

Pharmaceuticals

9 Jun 2020

Investment Date

100%

Stake

£ 3.29 B

Deal Value

mitobridge inc

HQ - Japan

Biotechnology

23 Jan 2018

Investment Date

n/a

Deal Value

ganymed pharmaceuticals ag

HQ - Germany

Pharmaceuticals

21 Dec 2016

Investment Date

n/a

Deal Value

astellas pharma (dermatology business)

HQ - Japan

Pharmaceuticals

31 Mar 2016

Investment Date

100%

Stake

£ 479 M

Deal Value

Explore deals beyond your search with a free MergerLinks account.

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy